A Sativex®-like combination of phytocannabinoids as a disease-modifying therapy in a viral model of multiple sclerosis

BACKGROUND AND PURPOSE: Sativex® is an oromucosal spray, containing equivalent amounts of Δ(9)-tetrahydrocannabinol (Δ(9)-THC) and cannabidiol (CBD)-botanical drug substance (BDS), which has been approved for the treatment of spasticity and pain associated to multiple sclerosis (MS). In this study,...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Br J Pharmacol
Autors principals: Feliú, A, Moreno-Martet, M, Mecha, M, Carrillo-Salinas, F J, de Lago, E, Fernández-Ruiz, J, Guaza, C
Format: Artigo
Idioma:Inglês
Publicat: John Wiley & Sons, Ltd 2015
Matèries:
Research Papers
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4507161/
https://ncbi.nlm.nih.gov/pubmed/25857324
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.13159
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars